Meeting
2015 ASCO Annual Meeting
Phase I study of vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced non-squamous non-small cell lung cancer (NSCLC).
Authors
Ranee Mehra
Fox Chase Cancer Center, Philadelphia, PA
Ranee Mehra , Aruna Turaka , Joshua E. Meyer , Brian L. Egleston , Tawee Tanvetyanon , Mary Colleen Pinder , Thomas J. Dilling , Charles C. Williams , Jhanelle Elaine Gray , Keisuke Shirai , R. Katherine Alpaugh , Debbie Riordan , Neeta Somaiah , Prashant C. Shah , Walter Joseph Scott , George R. Simon , Hossein Borghaei
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01059552
Citation
J Clin Oncol 33, 2015 (suppl; abstr 7553)
DOI
10.1200/jco.2015.33.15_suppl.7553
Abstract #
7553
Poster Bd #
301
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto
Poster
2020 ASCO Virtual Scientific Program
Base excision repair (BER) inhibitor TRC 102 (Methoxyamine) combined with pemetrexed (PEM)-based chemo-radiation (CRT) for locally advanced non-squamous non-small cell lung cancer (NS-NSCLC): Results of a phase I trial.
First Author: Tithi Biswas
Poster
2016 ASCO Annual Meeting
A phase 1 trial of vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced stage head and neck squamous cell carcinoma.
First Author: Theodoros Nicholas Teknos
Poster
2019 ASCO Annual Meeting
Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage III non–small-cell lung cancer (NSCLC): KEYNOTE-799.
First Author: Salma K. Jabbour